Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Dr Rajani Katta joins Ethics Talk to discuss her article, coauthored with Dina H. Zamil, Emily K. Burns, and Dr Ariadna Perez-Sanchez: “Do You Know How to Assess Risks Posed by Over-the-Counter Vitamin A Supplements?”